Serotonin and anxiety: a review of current research and clinical implications

ABSTRACT

Benzodiazepines [BNs] are known to pose risks associated with drug dependence, abuse and withdrawal symptoms. Arylpiperazines such as buspirone, gepirone and ipsapirone have been introduced as useful alternatives to/the BZs in the treatment of anxiety and depression, which are distinct illnesses and often coexist. This new class of drugs is distinguished from its predecessors by a wider margin of safety and a lower potential for fatal overdose. This article addresses salient issues and provides evidence in the burgeoning field of serotonin-related management of anxiety in clinical psychiatry